Search Within

Alexander Edward Drilon

  1. "Sarcoma Service"
Formats
  1. Journal Article (11)
  2. Meeting Abstract (5)
  3. Research Letter (1)
Groups
  1. Department of Medicine (17)
  2. Sarcoma Service (17)
  3. Solid Tumor Oncology Division (17)
  4. Thoracic Oncology (17)
  5. Early Drug Development Service (12)
  6. Department of Pathology and Laboratory Medicine (10)

More Groups

People
  1. Mrinal Gounder (12)
  2. David Hyman (11)
  3. James Harding (6)
  4. Alexia Iasonos (5)
  5. Bob Li (5)
  6. Marc Ladanyi (5)

More People

Years
  1. 2025 (1)
  2. 2022 (2)
  3. 2021 (1)
  4. 2020 (2)
  5. 2019 (1)
  6. 2018 (1)

More Years

Publications
  1. Journal of Clinical Oncology (4)
  2. Cancer (3)
  3. Annals of Oncology (2)
  4. Investigational New Drugs (2)
  5. American Journal of Surgical Pathology (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (4)
  2. Wiley Blackwell (3)
  3. Oxford University Press (2)
  4. Springer (2)
  5. American Association for Cancer Research (1)
  6. American Medical Association (1)

More Publishers

Results (17)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program
    Journal Article

    Drilon, A.; Eaton, A. A.; Schindler, K.; Gounder, M. M.; Spriggs, D. R.; Harris, P.; Ivy, S. P.; Iasonos, A.; Lacouture, M. E.; Hyman, D. M.
    Cancer (2016)

    Fulltext@MSK | Save
  • What hides behind the MASC: Clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
    Journal Article

    Drilon, A.; Li, G.; Dogan, S.; Gounder, M.; Shen, R.; Arcila, M.; Wang, L.; Hyman, D. M.; Hechtman, J.; Wei, G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Toxicity attribution in phase I trials: Evaluating the effect of dose on the frequency of related and unrelated toxicities
    Journal Article

    Eaton, A.; Iasonos, A.; Gounder, M. M.; Pamer, E. G.; Drilon, A.; Vulih, D.; Smith, G. L.; Ivy, S. P.; Spriggs, D. R.; Hyman, D. M.
    Clinical Cancer Research (2016)

    Fulltext@MSK | Save
  • Phase I trial of the HSP-90 inhibitor PU-H71
    Meeting Abstract

    Gerecitano, J. F.; Modi, S.; Rampal, R.; Drilon, A. E.; Fury, M. G.; Gounder, M. M.; Harding, J. J.; Hyman, D. M.; Varghese, A. M.; Voss, M. H.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Physician toxicity attribution in phase I trials: Evaluating the effect of dose on the frequency of 11,909 toxicities
    Meeting Abstract

    Eaton, A.; Iasonos, A.; Gounder, M. M.; Pamer, E.; Drilon, A. E.; Vulih, D.; Smith, G. L.; Ivy, P.; Spriggs, D. R.; Hyman, D. M.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Dermatologic toxicities of 3,517 solid tumor patients on phase I clinical trials of the National Institutes of Health Cancer Therapy Evaluation Program (CTEP)
    Meeting Abstract

    Drilon, A. E.; Eaton, A.; Schindler, K.; Gounder, M. M.; Smith, G. L.; Vulih, D.; Harris, P. J.; Spriggs, D. R.; Ivy, P.; Iasonos, A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Extraskeletal myxoid chondrosarcoma: A retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy
    Journal Article

    Drilon, A.; Popat, S.; Bhuchar, G.; D'adamo, D. R.; Keohan, M. L.; Fisher, C.; Antonescu, C. R.; Singer, S.; Brennan, M. F.; Judson, I.; more...
    Cancer (2008)

    Fulltext@MSK | Save